383 related articles for article (PubMed ID: 27535952)
1. Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Ingiliz P; Christensen S; Kimhofer T; Hueppe D; Lutz T; Schewe K; Busch H; Schmutz G; Wehmeyer MH; Boesecke C; Simon KG; Berger F; Rockstroh JK; Schulze zur Wiesch J; Baumgarten A; Mauss S
Clin Infect Dis; 2016 Nov; 63(10):1320-1324. PubMed ID: 27535952
[TBL] [Abstract][Full Text] [Related]
2. Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
Corma-Gómez A; Macías J; Merino Muñoz D; Téllez F; Granados R; Morano LE; De Los Santos Gil I; Vera-Méndez FJ; Collado A; Palacios R; Pineda JA
J Infect; 2019 Jul; 79(1):30-35. PubMed ID: 31100364
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
6. Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.
Sawinski D; Lee DH; Doyle AM; Blumberg EA
Transplantation; 2017 May; 101(5):974-979. PubMed ID: 27467534
[TBL] [Abstract][Full Text] [Related]
7. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population.
Banga J; Nizami S; Slim J; Nagarakanti S; Portilla M; Swaminathan S
Medicine (Baltimore); 2020 Mar; 99(11):e19140. PubMed ID: 32176039
[TBL] [Abstract][Full Text] [Related]
9. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
Townsend K; Petersen T; Gordon LA; Kohli A; Nelson A; Seamon C; Gross C; Tang L; Osinusi A; Polis MA; Masur H; Kottilil S
AIDS; 2016 Jan; 30(2):261-6. PubMed ID: 26691547
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
Gane EJ; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CAM
Gastroenterology; 2017 May; 152(6):1366-1371. PubMed ID: 28137593
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Naggie S; Cooper C; Saag M; Workowski K; Ruane P; Towner WJ; Marks K; Luetkemeyer A; Baden RP; Sax PE; Gane E; Santana-Bagur J; Stamm LM; Yang JC; German P; Dvory-Sobol H; Ni L; Pang PS; McHutchison JG; Stedman CA; Morales-Ramirez JO; Bräu N; Jayaweera D; Colson AE; Tebas P; Wong DK; Dieterich D; Sulkowski M;
N Engl J Med; 2015 Aug; 373(8):705-13. PubMed ID: 26196665
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
[TBL] [Abstract][Full Text] [Related]
13. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.
Rockstroh JK; Bhagani S; Hyland RH; Yun C; Dvory-Sobol H; Zheng W; Brainard DM; Ingiliz P; Lutz T; Boesecke C; Nelson M
Lancet Gastroenterol Hepatol; 2017 May; 2(5):347-353. PubMed ID: 28397698
[TBL] [Abstract][Full Text] [Related]
14. Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Uemura H; Tsukada K; Mizushima D; Aoki T; Watanabe K; Kinai E; Teruya K; Gatanaga H; Kikuchi Y; Sugiyama M; Mizokami M; Oka S
PLoS One; 2017; 12(10):e0186255. PubMed ID: 29045448
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Rosenthal E; Fougerou-Leurent C; Renault A; Carrieri MP; Marcellin F; Garraffo R; Teicher E; Aumaitre H; Lacombe K; Bailly F; Billaud E; Chevaliez S; Dominguez S; Valantin MA; Reynes J; Naqvi A; Cotte L; Metivier S; Leroy V; Dupon M; Allegre T; De Truchis P; Jeantils V; Chas J; Salmon-Ceron D; Morlat P; Neau D; Perré P; Piroth L; Pol S; Bourlière M; Pageaux GP; Alric L; Zucman D; Girard PM; Poizot-Martin I; Yazdanpanah Y; Raffi F; Pabic EL; Tual C; Pailhé A; Amri I; Bellissant E; Molina JM;
HIV Med; 2018 Mar; 19(3):227-237. PubMed ID: 29214737
[TBL] [Abstract][Full Text] [Related]
16. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
17. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
18. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
[TBL] [Abstract][Full Text] [Related]
19. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
Walsh CE; Workowski K; Terrault NA; Sax PE; Cohen A; Bowlus CL; Kim AY; Hyland RH; Han B; Wang J; Stamm LM; Brainard DM; McHutchison JG; von Drygalski A; Rhame F; Fried MW; Kouides P; Balba G; Reddy KR
Haemophilia; 2017 Mar; 23(2):198-206. PubMed ID: 28124511
[TBL] [Abstract][Full Text] [Related]
20. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
